Lupus nephritis is a serious complication of lupus — and because it doesn’t always cause symptoms right away, it’s important to find it early. Talk to your lupus doctor about getting screened (tested) ...

Lupkynis is a medicine that is used for a specific kidney disease called lupus nephritis. Lupus nephritis is a kidney condition that affects people with systemic lupus erythematosus (SLE). SLE is an ...

Please provide your email address to receive an email when new articles are posted on . Lupus nephritis (LN) is a serious and potentially life-threatening complication of systemic lupus erythematosus ...

Interstitial nephritis is a kidney condition characterized by swelling in between the kidney tubules. The main functions of your kidneys are to filter your blood and to get rid of waste from your body ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patients with ...

DESTIN, Fla. — Patients who develop lupus nephritis within their first year of being diagnosed with systemic lupus erythematosus have a 23.2% risk of renal failure within 20 years, according to ...

Achieving and maintaining long-term clinical remission may prevent impaired kidney function in patients with lupus nephritis. Sustained clinical remission of lupus nephritis (LN) protects against ...

Nephritis is an inflammation of the nephrons, which are part of the kidneys. Also known as glomerulonephritis, it can affect kidney function, leading to changes in urine and urination habits and ...

The Food and Drug Administration (FDA) has expanded the approval of Benlysta (belimumab) to include pediatric patients 5 to 17 years of age with active lupus nephritis who are receiving standard ...

Lupus low disease activity state is a valid treatment target for patients with lupus nephritis associated with renal function preservation. Achieving both Lupus Low Disease Activity State (LLDAS) and ...

Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis ...